Ocular Therapeutix (OCUL) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Stoke Therapeutics (STOK) has outperformed Ocular Therapeutix (OCUL) over the past year, losing 11.1% versus a loss of 37.2%. Over five years, STOK leads with a +3.3% price change compared with -35.4% for OCUL. Ocular Therapeutix is the larger company by market cap ($1.59 billion vs $1.57 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCUL | STOK |
|---|---|---|
| Share price | $7.23 | $24.29 |
| Market cap | $1.59B | $1.57B |
| 1-day change | -1.50% | -0.33% |
| YTD return | -40.44% | -23.47% |
| 1-year return | -37.24% | -11.06% |
| 5-year return | -35.39% | +3.27% |
| EPS (TTM) | $-1.38 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.44 | $40.22 |
| 52-week low | $6.23 | $20.32 |
| Distance from 52-week high | -56.02% | -39.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +274.69% | +91.27% |
| Average volume | 2.78M | 855.44K |
| Shares outstanding | 219.62M | 64.53M |
| Employees | 325 | 170 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STOK has outperformed OCUL by 26.2 percentage points over the past year.
- The two companies sit in different sectors: Ocular Therapeutix in Health Care and Stoke Therapeutics in Healthcare.
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Healthcare · Biotechnology · 170 employees
OCUL vs STOK FAQ
Which is bigger, Ocular Therapeutix or Stoke Therapeutics?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.59B compared with $1.57B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, OCUL or STOK?
STOK returned -11.06% over the past 12 months, compared with -37.24% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Ocular Therapeutix and Stoke Therapeutics in the same industry?
No. Ocular Therapeutix is in the Health Care sector, while Stoke Therapeutics is in Healthcare.